Streetbeat News

Analyst Ratings

COIN

Needham analyst John Todaro reiterated a Buy rating on Coinbase Global (NASDAQ:COIN) and maintained a $70 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:18 am

PKST

B of A Securities analyst Joshua Dennerlein initiates coverage on Peakstone Realty Trust (NYSE:PKST) with an Underperform rating and a price target of $27.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:18 am

KDNY

SVB Leerink analyst Joseph Schwartz downgraded Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Market Perform and lowered the price target from $44 to $40.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:16 am

VACC

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Vaccitech (NASDAQ:VACC) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:14 am

OCUL

HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) and raises the price target from $10 to $12.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:13 am

KDNY

HC Wainwright & Co. analyst Ed Arce downgraded Chinook Therapeutics (NASDAQ:KDNY) from Buy to Neutral and announced a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:12 am

APLS

HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintains a $100 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:10 am

IMGN

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $15 to $21.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:09 am

SPRB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spruce Biosciences (NASDAQ:SPRB) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 10:09 am

PERI

Needham analyst Laura Martin has reiterated a Buy rating on Perion Network (NASDAQ:PERI) and maintained a $42 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 9:59 am